X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

DoKaSch Temperature Solutions strengthens presence in Japan

Content Team by Content Team
7th December 2021
in News
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

DoKaSch Temperature Solutions continues to expand its business in Asia. With the dedicated subsidiary DoKaSch Temperature Solutions K.K. in Tokyo and a new service station at Narita International Airport, customers in Japan now have optimal access to the “Opticooler” – high-quality and reliable temperature-controlled packaging-solution by DoKaSch Temperature Solutions. Additionally, the specialist for temperature-controlled packaging solutions will be presenting its active container solutions at INTERPHEX Japan 2021 from December 8 to 10 at booth 8-36.

Japan is considered an important production and export center for pharmaceuticals in the Asian-Pacific region as well as worldwide. Especially in terms of biopharmaceuticals and vaccines, the demand for pharmaceutical cold chain capacity is increasing. Narita International Airport has one of the largest temperature-controlled storage facilities for airports in Japan, the Cargo Climate Control Terminal (CCC). The airport handles half of all pharmaceutical trade in Japan, making it one of the most important hubs for both import and export.

With its office in Tokyo and the new depot at Narita International Airport, DoKaSch Temperature Solutions is strengthening its network in the region and worldwide. In this way, the solution provider for temperature-controlled packaging contributes to a reliable cold chain for highly sensitive pharmaceutical products, especially during the pandemic. The capacities of RKN and RAP Opticooler at Narita Station can be increased at any time and immediately so that the required number of containers is available for each flight. Back in July, for example, DoKaSch Temperature Solutions K.K. provided Opticoolers for a large-scale and very important transport operation of vaccines.

“I see many opportunities for Opticooler in the important Japanese pharmaceutical market and beyond, because of its technical characteristics, exceptional reliability and availability. Because of our proximity and extensive network, we can serve customers quickly and reliably,” says Kazuyoshi Kakizawa, Head of DoKaSch Temperature Solutions K.K.. The experienced industry expert is responsible for the further development and expansion of DoKaSch’s business in Japan and also for the company’s operational activities in the East Asian island state.

Andreas Seitz, Managing Director of DoKaSch Temperature Solutions, adds: “Japan is a major production and export center for pharmaceuticals and biopharmaceuticals. Therefore, we decided to open a new DoKaSch office and station at Tokyo. It is directly related to our growth strategy in Asia and ideally complements our extensive global network. This allows us to further ensure that our Opticooler reaches our customers quickly and thus contribute to a smooth and reliable cold chain.”

DoKaSch’s Opticooler is an extremely reliable, temperature-controlled packaging solution. Electrically powered and fully climate controlled, the active containers can both cool and heat without using dry ice or other refrigerants. They maintain the desired temperature level, e.g. between 2° and 8° Celsius at all times and regardless of external climatic conditions. This makes them the ideal solution for the safe transport of highly sensitive and valuable pharmaceutical products that must always be protected from temperature fluctuations. Customers who would like to see and inform about the Opticooler can meet Kazuyoshi Kakizawa at this year’s INTERPHEX Japan 2021 from December 8 to 10 at booth 8-36.

INTERPHEX Japan 2021 is Japan’s largest exhibition for pharmaceutical and cosmetics manufacturing/packaging technologies. With 23 years of history, INTERPHEX Japan is known as the best business platform to network with industry top leaders from pharmaceutical and cosmetics industry in Japan and Asia. The show is held inside INTERPHEX Week Tokyo; Asia’s leading comprehensive pharma and cosmetics event.

Previous Post

Concept Life Sciences celebrates GMP accreditation

Next Post

CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In